
Zhiming Min Zeng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7640526/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CXC195 suppresses proliferation and inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway. Biochemical and Biophysical Research Communications, 2015, 456, 373-379.	2.1	59
2	Osimertinib combined with bevacizumab for leptomeningeal metastasis from <scp><i>EGFR</i>â€mutation nonâ€small cell</scp> lung cancer: A phase <scp>II singleâ€arm</scp> prospective clinical trial. Thoracic Cancer, 2021, 12, 172-180.	1.9	20
3	Radiation‑induced dysfunction of energy metabolism in the heart results in the fibrosis of cardiac tissues. Molecular Medicine Reports, 2021, 24, .	2.4	19
4	BRCA1 protects cardiac microvascular endothelial cells against irradiation by regulating p21-mediated cell cycle arrest. Life Sciences, 2020, 244, 117342.	4.3	18
5	Derlinâ€l exhibits oncogenic activities and indicates an unfavorable prognosis in breast cancer. Cell Biology International, 2020, 44, 593-602.	3.0	9
6	Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study. BMC Cancer, 2021, 21, 873.	2.6	9
7	Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cellâ€,lungâ€,cancer: a propensity-matched retrospective study. BMC Cancer, 2021, 21, 482.	2.6	8
8	Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer. Journal of Translational Medicine, 2022, 20, 122.	4.4	8
9	Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleSTâ€2, in thoracic cancer chest radiation. Journal of Clinical Laboratory Analysis, 2020, 34, e23150.	2.1	5
10	Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer. Medicine (United States), 2021, 100, e27279.	1.0	5
11	PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model. International Immunopharmacology, 2022, 105, 108551.	3.8	4
12	Characteristics and outcomes of primary pleural angiosarcoma. Medicine (United States), 2022, 101, e28785.	1.0	4
13	The three-dimensional printed template guided technique for S2 alar iliac screw placement and a comparison with freehand technique. Journal of Orthopaedic Surgery, 2020, 28, 230949902096711.	1.0	3
14	EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report. OncoTargets and Therapy, 2021, Volume 14, 2823-2828.	2.0	3
15	Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report. Frontiers in Oncology, 2021, 11, 720819.	2.8	3
16	Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib. Lung Cancer, 2021, 155, 170-174.	2.0	2
17	Primary pleural epithelioid angiosarcoma treated successfully with anti-PD-1 therapy. Medicine (United States), 2021, 100, e27132.	1.0	2
18	Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database. Radiation Oncology, 2021, 16, 184.	2.7	2